Markets

USAR|EPS -$0.19|Rev $1.6M|Net Loss $50.5M USA Rare Earth, Inc. reported a loss of $0.19 per share for the fourth quarter of 2025, as the rare earth minerals developer continues to invest heavily in its operations. The company generated $1.6M in revenue for the quarter while posting a net loss of $50.5M for the period. The […]

BCAX|EPS -$0.68|Net Loss $37.4M Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. As a clinical-stage company, Bicara’s financial statements did not report any revenue for 2025. The company reported a basic and diluted Earnings Per Share (EPS) net loss of $(0.68) for the fourth quarter

PDSB|EPS -$0.74|Net Loss $34.5M PDS Biotechnology Corporation reported a full-year 2025 loss per share of -$0.74, marking a significant improvement from the year-ago period as the clinical-stage biopharmaceutical company continues to advance its pipeline of targeted cancer immunotherapies. The loss narrowed 28.2% compared to the -$1.03 per share loss recorded in FY 2024. The company

NMRA|EPS -$0.35|Net Loss $59.4M Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for brain diseases. Based on the provided financial statements, the company did not report any revenue for 2024 or 2025. The basic and diluted net loss per share (EPS) was $(1.45) for the full year 2025, an improvement from

USAS|EPS -$0.13 vs $0.04 est (-425.0%)|Rev $118.0M vs $65.3M est (+80.8%)|Net Loss $87.4M Americas Gold and Silver Corporation reported a loss of $0.13 per share for the full year of 2025, missing analyst expectations of $0.04 earnings per share by 425.0% based on estimates from 1 analyst. The mining company posted a net loss of

CBAT|EPS -$0.10|Rev $195.1M|Net Loss $9.4M CBAK Energy Technology, Inc. posted a loss per share of $0.10 for the full year of 2025, a sharp reversal from earnings of $0.13 last year, representing a 176.9% decline. The lithium and sodium battery manufacturer reported a net loss of $9.4M for the year despite strong revenue expansion. The

RVPH|EPS -$5.48|Net Loss $19.9M Reviva Pharmaceuticals is a late-stage pharmaceutical company developing therapies for central nervous system, inflammatory, and cardiometabolic diseases. For the full year ended December 31, 2025, Reviva reported an earnings per share (EPS) equivalent to a net loss of $5.48 per share. The company’s consolidated statements of operations did not report any

CV|EPS -$1.03|Rev $13.6M|Net Loss $25.3M CapsoVision is a commercial-stage medical technology company that develops advanced imaging and AI-enabled capsule endoscopy solutions.   For the full year 2025, the company reported revenue of $13.6 million, marking a 15% increase compared to the full year 2024. Fourth quarter 2025 revenue was $3.9 million. The reported net loss per